SAN DIEGO , Feb.  05, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Jasper Therapeutics, Inc. (NASDAQ:JSPR), KBR, Inc. (NYSE:KBR),

JSPR

Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 SAN DIEGO , Feb. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Jasper Therapeutics, Inc. (NASDAQ:JSPR), KBR, Inc. (NYSE:KBR),
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Johnson Fistel is probing Jasper Therapeutics for potential fiduciary breaches by leadership based on allegations of misleading statements and inadequate operational controls. This situation may impair the company&#039;s product prospects and financial standing, increasing risks for investors. Governance reforms are sought by shareholders who held shares since November 30, 2023.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Johnson Fistel is investigating claims against JSPR&#039;s directors.</li><li>Shareholders before November 30, 2023, can seek governance reforms.</li><li>Allegations include misleading statements and inadequate manufacturing controls.</li><li>Legal issues may impact JSPR&#039;s product prospects and financials.</li><li>Investors face risks related to ongoing class action complaints.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>KBR, Inc. (KBR): Also facing examination for similar fiduciary breaches.</li><li>LifeMD, Inc. (LFMD): Included in investigations concerning governance and operational claims.</li><li>Lineage, Inc. (LINE): Investigated for misleading statements affecting its IPO performance.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This news falls under &#039;Corporate Developments,&#039; highlighting governance issues affecting company stability. JSPR&#039;s ongoing legal challenges may lead to significant changes in operational oversight and investor sentiment.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Fiduciary duty breaches may lead to changes in executive oversight.</li><li>Ongoing legal investigations could deter investor confidence in JSPR.</li><li>Allegations may impede regulatory approvals for product candidates.</li><li>Potential governance reforms might unlock shareholder value.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Jasper Therapeutics is facing an investigation by Johnson Fistel.</li><li>Shareholders must have held shares since November 30, 2023, to participate.</li><li>The investigation concerns alleged misleading statements by JSPR&#039;s leadership.</li><li>Allegations cite deficiencies in manufacturing compliance and product trials.</li><li>The investigations could lead to corporate governance reforms.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Consider a cautious approach to JSPR, anticipating potential short-term volatility.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>SAN DIEGO , Feb. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Jasper Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/JSPR">JSPR</a>), KBR, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/KBR">KBR</a>), LifeMD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LFMD">LFMD</a>), and Lineage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LINE">LINE</a>) against certain of their officers and directors for alleged breaches of fiduciary duty. Shareholders who have held shares continuously since prior to the dates listed below may have standing to seek corporate governance reforms focused on executive oversight, the return of funds to the Company, and a court-approved incentive award, at no cost to them. Jasper Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/JSPR">JSPR</a>) If you have held Jasper Therapeutics shares continuously since prior to November 30, 2023, you may have standing to seek corporate governance reforms focused on executive oversight at Jasper Therapeutics. To learn more, visit: <a href="https://www.globenewswire.com/Tracker?data=83c9ToyOFKHM_orGJz-dQ60KByAxPiTCzcczn4UH1pi3MSdj77dFh7Vm6tmRIv8xfukTQ2BIotDH5BDcPcqa8X6t-Ms19-ljRUxpLTJZrgGQ4gMF-iuD_GgcKvikK_gSae43Hg71_Hn0N0D9iGbOleSU5XxuY3psZrEaFAutODRgBQcgRVM9INy9-YmhClhujwNsQhlAEfSz7PMMVRg2F7OR19ikVjtaiKFRCUszbik=" rel="nofollow" target="_blank">https://www.johnsonfistel.com/investigations/jasper-therapeutics-inc/</a> or contact Johnson Fistel, PLLP at jimb@johnsonfistel.com or (619) 814-4471. Complaint Allegations A previously filed securities class action complaint alleges that throughout the class period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked adequate controls and procedures to ensure that third-party manufacturers were producing products in full compliance with cGMP requirements and otherwise suitable for clinical trial use; (2) these deficiencies increased the risk that clinical study results would be confounded, adversely impacting the regulatory and commercial prospects of the Company's product candidates, including briquilimab; (3) these issues increased the likelihood that Jasper would be forced to implement disruptive cost-reduction measures; (4) as a result, the Company's business and financial prospects were overstated; and (5) Defendants' positive statements regarding the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. KBR, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/KBR">KBR</a>) If you have held KBR shares continuously since prior to May 6, 2025, you may have standing to seek corporate governance reforms focused on executive oversight at KBR. To learn more, visit: <a href="https://www.globenewswire.com/Tracker?data=83c9ToyOFKHM_orGJz-dQ60KByAxPiTCzcczn4UH1pi3MSdj77dFh7Vm6tmRIv8xe2RKCvB82odPtD0MVgzIsFWttxUE5IMr__1YB2DbGlWA2SLtxvHrLA4CaO2wLWrOY6yAw_AVydcjEtH9uX25erA-I5S0u_D3_Kh_cI6x48c=" rel="nofollow" target="_blank">https://www.johnsonfistel.com/investigations/kbr/</a> or contact Johnson Fistel, PLLP at jimb@johnsonfistel.com or (619) 814-4471. Complaint Allegations A previously filed securities class action complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that, despite having knowledge that the U.S. Department of Defense's Transportation Command had expressed material concerns for months regarding HomeSafe's ability to perform under the Global Household Goods Contract, Defendants publicly represented that the partnership was proceeding as planned and would ramp in future quarters. According to the complaint, these statements lacked a reasonable basis and rendered Defendants' representations regarding KBR's business, operations, and prospects materially false or misleading. LifeMD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LFMD">LFMD</a>) If you have held LifeMD shares continuously since prior to May 7, 2025, you may have standing to seek corporate governance reforms focused on executive oversight at LifeMD. To learn more, visit: <a href="https://www.globenewswire.com/Tracker?data=83c9ToyOFKHM_orGJz-dQ60KByAxPiTCzcczn4UH1pi3MSdj77dFh7Vm6tmRIv8x-gXHfSBHSCTT0eTWEebdZ8Wn6jOG54J1vljYYCbdvVaWI56qfWCMYURIr5QTSxSNruDPS7kfaaLpoKGT9YGS2MHwiSDmx68uptokbBR4LtHCbjGvARpM9sYt7YiKz63T" rel="nofollow" target="_blank">https://www.johnsonfistel.com/investigations/lifemd/</a> or contact Johnson Fistel, PLLP at jimb@johnsonfistel.com or (619) 814-4471. Complaint Allegations A previously filed securities class action complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) LifeMD's competitive position was materially overstated; (2) Defendants were reckless in raising the Company's 2025 guidance without adequately accounting for rising customer acquisition costs in LifeMD's RexMD segment and customer acquisition costs associated with the sale of obesity drugs, including Wegovy and Zepbound; and (3) as a result, Defendants' statements regarding the Company's business, operations, and prospects were materially false or misleading and/or lacked a reasonable basis. Lineage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LINE">LINE</a>) If you purchased Lineage common stock in or traceable to the Company's July 2024 initial public offering and have held shares continuously since that time, you may have standing to seek corporate governance reforms focused on executive oversight at Lineage. To learn more, visit: <a href="https://www.globenewswire.com/Tracker?data=83c9ToyOFKHM_orGJz-dQ60KByAxPiTCzcczn4UH1pi3MSdj77dFh7Vm6tmRIv8xlc3RbB6aeOBIuBCz5ph-C3CQQTuB15cmLpezzErv1FAgPB1rOIoBlQx23EuTURXLKfEUcfbTuwrqnHLxt6iFsWa_JAAPYVaAU8vpguBeZXff-6LlZYSBhWZanvXYp-MI" rel="nofollow" target="_blank">https://www.johnsonfistel.com/investigations/lineage-inc/</a> or contact Johnson Fistel, PLLP at jimb@johnsonfistel.com or (619) 814-4471. Complaint Allegations A previously filed securities class action complaint alleges that the registration statement issued in connection with Lineage's July 2024 IPO was false and/or misleading and/or failed to disclose that: (1) Lineage was experiencing sustained weakening customer demand due to increased cold-storage supply, customer destocking, and a shift toward leaner inventories; (2) price increases implemented prior to the IPO were unsustainable in light of these conditions; (3) Lineage was unable to offset these trends through minimum storage guarantees, operational efficiencies, or technological improvements; (4) as a result, Lineage was experiencing stagnant or declining revenue, occupancy rates, and rental pricing; and (5) the Company's business, financial results, and prospects were materially impaired. About Johnson Fistel, PLLP &#x7C; Top Law Firm, Securities Fraud, Investor Rights Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also represents foreign investors who have purchased securities on U.S. exchanges. Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content. Contact: Johnson Fistel, PLLP 501 W. Broadway, Suite 800 San Diego, CA 92101 James Baker &#x7C; (619) 814-4471 <a href="https://www.globenewswire.com/Tracker?data=lJX9NvColac32gNrtKP5q0zlMOBc9GUHOo2ws3qoWh-xofrOCMShchhPpMGlaO7ThXEhT5AzWuijYPxoAhCgkHKl5Sa7DZDlascJMpFmFF8=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a>  <a href="https://www.globenewswire.com/Tracker?data=83c9ToyOFKHM_orGJz-dQ60KByAxPiTCzcczn4UH1pgFHAdfNde3JBYIbJiwYv-eJkgJzUZDpkAv1lFog5Zj59J0AS79fEN5qkIV2jiraEh5Z6hyXMD63E9QxoLw9leV" rel="nofollow" target="_blank">https://www.johnsonfistel.com/</a> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY0OTYyNyM3NDA5MjQ3IzIxODE3ODk="></img> <img alt="" src="https://ml.globenewswire.com/media/YzgxMTgyMDYtYTg4YS00ZThkLWI4OWQtODAyZmQ0Yzc0ZWE3LTExOTMzNTgtMjAyNi0wMi0wNS1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a>

Johnson Fistel is probing Jasper Therapeutics for potential fiduciary breaches by leadership based on allegations of misleading statements and inadequate operational controls. This situation may impair the company's product prospects and financial standing, increasing risks for investors. Governance reforms are sought by shareholders who held shares since November 30, 2023.

johnson-fistel-pllp-begins-investigation-on-behalf-of-long-term-shareholders-of-jasper-therapeutics-inc-jspr-kbr-inc-kbr-lifemd-inc-lfmd-and-lineage-inc-line

Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News